spironolactone has been researched along with Cognition Disorders in 6 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Spironolactone treatment also improved cognitive function in ovariectomized-KKAy mice, but failed to improve it in those with administration of estradiol (200 µg/kg per day)." | 1.38 | Improvement of cognitive impairment in female type 2 diabetes mellitus mice by spironolactone. ( Horiuchi, M; Ito, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Ohshima, K; Sakata, A; Tsukuda, K, 2012) |
| "86), and chronic use of spironolactone (OR, 2." | 1.37 | Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. ( Bastuji-Garin, S; Bedane, C; Bernard, P; Delaporte, E; Dutronc, Y; Guillaume, JC; Ingen-Housz-Oro, S; Joly, P; Lemordant, P; Maillard, H; Pauwels, C; Picard-Dahan, C; Richard, MA; Roujeau, JC; Sparsa, A, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bastuji-Garin, S | 1 |
| Joly, P | 1 |
| Lemordant, P | 1 |
| Sparsa, A | 1 |
| Bedane, C | 1 |
| Delaporte, E | 1 |
| Roujeau, JC | 1 |
| Bernard, P | 1 |
| Guillaume, JC | 1 |
| Ingen-Housz-Oro, S | 1 |
| Maillard, H | 1 |
| Pauwels, C | 1 |
| Picard-Dahan, C | 1 |
| Dutronc, Y | 1 |
| Richard, MA | 1 |
| Sakata, A | 1 |
| Mogi, M | 1 |
| Iwanami, J | 1 |
| Tsukuda, K | 1 |
| Min, LJ | 1 |
| Jing, F | 1 |
| Ohshima, K | 1 |
| Ito, M | 1 |
| Horiuchi, M | 1 |
| Cornelisse, S | 1 |
| Joëls, M | 1 |
| Smeets, T | 1 |
| SoRelle, R | 1 |
| Smythe, JW | 1 |
| Murphy, D | 1 |
| Timothy, C | 1 |
| Gul, GH | 1 |
| Costall, B | 1 |
| Taylor, JW | 1 |
1 trial available for spironolactone and Cognition Disorders
| Article | Year |
|---|---|
A randomized trial on mineralocorticoid receptor blockade in men: effects on stress responses, selective attention, and memory.
Topics: Adolescent; Adult; Attention; Cognition Disorders; Double-Blind Method; Humans; Hypothalamo-Hypophys | 2011 |
5 other studies available for spironolactone and Cognition Disorders
| Article | Year |
|---|---|
Risk factors for bullous pemphigoid in the elderly: a prospective case-control study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Bed Rest; Bipolar Disorder; Case-Control Studies; Cog | 2011 |
Improvement of cognitive impairment in female type 2 diabetes mellitus mice by spironolactone.
Topics: Animals; Blood Pressure; Body Weight; Cognition Disorders; Diabetes Mellitus, Type 2; Electrolytes; | 2012 |
Two better than one.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Animals; Class Ib Phosphatidylinositol 3-Kina | 2003 |
Cognitive dysfunctions induced by scopolamine are reduced by systemic or intrahippocampal mineralocorticoid receptor blockade.
Topics: Animals; Cognition Disorders; Hippocampus; Injections; Injections, Intraperitoneal; Male; Maze Learn | 1997 |
Mental symptoms and electrolyte imbalance.
Topics: Aged; Chlorine; Cognition Disorders; Confusion; Depression; Diuretics; Female; Humans; Hyponatremia; | 1979 |